BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31649014)

  • 1. Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer.
    Whalen KA; White BH; Quinn JM; Kriksciukaite K; Alargova R; Au Yeung TP; Bazinet P; Brockman A; DuPont MM; Oller H; Gifford J; Lemelin CA; Lim Soo P; Perino S; Moreau B; Sharma G; Shinde R; Sweryda-Krawiec B; Bilodeau MT; Wooster R
    Mol Cancer Ther; 2019 Nov; 18(11):1926-1936. PubMed ID: 31649014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo.
    White BH; Whalen K; Kriksciukaite K; Alargova R; Au Yeung T; Bazinet P; Brockman A; DuPont M; Oller H; Lemelin CA; Lim Soo P; Moreau B; Perino S; Quinn JM; Sharma G; Shinde R; Sweryda-Krawiec B; Wooster R; Bilodeau MT
    J Med Chem; 2019 Mar; 62(5):2708-2719. PubMed ID: 30735385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugate Targeting c-Kit for the Treatment of Small Cell Lung Cancer.
    Kim KH; Kim JO; Park JY; Seo MD; Park SG
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models.
    Morimura O; Minami T; Kijima T; Koyama S; Otsuka T; Kinehara Y; Osa A; Higashiguchi M; Miyake K; Nagatomo I; Hirata H; Iwahori K; Takimoto T; Takeda Y; Kida H; Kumanogoh A
    Biochem Biophys Res Commun; 2017 Jul; 488(4):596-602. PubMed ID: 28526406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer.
    Yagishita S; Fujita Y; Kitazono S; Ko R; Nakadate Y; Sawada T; Kitamura Y; Shimoyama T; Maeda Y; Takahashi F; Takahashi K; Tamura T; Koizumi F
    Mol Cancer Ther; 2015 Jun; 14(6):1414-23. PubMed ID: 25833836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.
    Whiteman KR; Johnson HA; Mayo MF; Audette CA; Carrigan CN; LaBelle A; Zukerberg L; Lambert JM; Lutz RJ
    MAbs; 2014; 6(2):556-66. PubMed ID: 24492307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using
    Qin S; Yang Y; Zhang J; Yin Y; Liu W; Zhang H; Fan X; Yang M; Yu F
    Mol Pharm; 2023 Nov; 20(11):5543-5553. PubMed ID: 37788300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.
    Giffin MJ; Cooke K; Lobenhofer EK; Estrada J; Zhan J; Deegen P; Thomas M; Murawsky CM; Werner J; Liu S; Lee F; Homann O; Friedrich M; Pearson JT; Raum T; Yang Y; Caenepeel S; Stevens J; Beltran PJ; Canon J; Coxon A; Bailis JM; Hughes PE
    Clin Cancer Res; 2021 Mar; 27(5):1526-1537. PubMed ID: 33203642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
    Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
    J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
    Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
    Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjudin synergizes with paclitaxel and inhibits cell growth and metastasis by regulating the sirtuin 3-Forkhead box O3a axis in human small-cell lung cancer.
    Wang X; Zeng Q; Li Z; Yang X; Xia W; Chen Z
    Thorac Cancer; 2019 Apr; 10(4):642-658. PubMed ID: 30779316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RYZ101 (Ac-225 DOTATATE) Opportunity beyond Gastroenteropancreatic Neuroendocrine Tumors: Preclinical Efficacy in Small-Cell Lung Cancer.
    Han G; Hwang E; Lin F; Clift R; Kim D; Guest M; Bischoff E; Moran S; Li G
    Mol Cancer Ther; 2023 Dec; 22(12):1434-1443. PubMed ID: 37616528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.
    Zhou J; Chen J; Zhong R; Mokotoff M; Shultz LD; Ball ED
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2224-31. PubMed ID: 16609038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin receptor 2 signaling promotes growth and tumor survival in small-cell lung cancer.
    Lehman JM; Hoeksema MD; Staub J; Qian J; Harris B; Callison JC; Miao J; Shi C; Eisenberg R; Chen H; Chen SC; Massion PP
    Int J Cancer; 2019 Mar; 144(5):1104-1114. PubMed ID: 30152518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.
    Merlino G; Fiascarelli A; Bigioni M; Bressan A; Carrisi C; Bellarosa D; Salerno M; Bugianesi R; Manno R; Bernadó Morales C; Arribas J; Dusek RL; Ackroyd JE; Pham PH; Awdew R; Aud D; Trang M; Lynch CM; Terrett J; Wilson KE; Rohlff C; Manzini S; Pellacani A; Binaschi M
    Mol Cancer Ther; 2019 Sep; 18(9):1533-1543. PubMed ID: 31227646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer.
    Huhe M; Lou J; Zhu Y; Zhao Y; Shi Y; Wang B; Sun X; Zhang X; Zhang Y; Chen ZN
    Biochem Biophys Res Commun; 2019 Jun; 513(4):1083-1091. PubMed ID: 31010682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.
    Gaponova AV; Nikonova AS; Deneka A; Kopp MC; Kudinov AE; Skobeleva N; Khazak V; Ogawa LS; Cai KQ; Duncan KE; Duncan JS; Egleston BL; Proia DA; Boumber Y; Golemis EA
    Clin Cancer Res; 2016 Oct; 22(20):5120-5129. PubMed ID: 27267850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective M3 muscarinic receptor antagonist inhibits small-cell lung carcinoma growth in a mouse orthotopic xenograft model.
    Ami N; Koga K; Fushiki H; Ueno Y; Ogino Y; Ohta H
    J Pharmacol Sci; 2011; 116(1):81-8. PubMed ID: 21512307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating
    Lakes AL; An DD; Gauny SS; Ansoborlo C; Liang BH; Rees JA; McKnight KD; Karsunky H; Abergel RJ
    Mol Pharm; 2020 Nov; 17(11):4270-4279. PubMed ID: 33044830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
    Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
    Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.